[1] STOREY R F. Pharmacology and clinical trials of

reversibly-binding p2y12 inhibitors[J/OL]. Thromb

Haemost，2011，105 Suppl 1：S75-S81. https：//doi.

org/10.1160/THS10-12-0769.

[2] WALLENTIN L，BECKER R C，BUDAJ A，et al.

Ticagrelor versus clopidogrel in patients with acute

coronary syndromes[J]. N Engl J Med，2009，361

（11）：1045-1057.

[3] WANG Y，MINEMATSU K，WONG K S，et al.

Ticagrelor in acute stroke or transient ischemic

attack in asian patients：From the socrates trial

（acute stroke or transient ischemic attack treated

with aspirin or ticagrelor and patient outcomes）[J].

Stroke，2017，48（1）：167-173.

[4] WANG Y，WANG Y，ZHAO X，et al. Clopidogrel

with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med，2013，369（1）：

11-19.

[5] WANG Y，ZHAO X，LIN J，et al. Association

between cyp2c19 loss-of-function allele status and

efficacy of clopidogrel for risk reduction among

patients with minor stroke or transient ischemic

attack[J]. JAMA，2016，316（1）：70-78.

[6] WANG Y，LIN Y，MENG X，et al. Effect of

ticagrelor with clopidogrel on high on-treatment

platelet reactivity in acute stroke or transient

ischemic attack（prince）trial：Rationale and

design[J]. Int J Stroke，2017，12（3）：321-325.

[7] AIT-MOKHTAR O，BONELLO L，BENAMARA S，

et al. High on treatment platelet reactivity[J]. Heart

Lung Circ，2012，21（1）：12-21.

[8] ARADI D，KOMOCSI A，VOROBCSUK A，et

al. Prognostic significance of high on-clopidogrel

platelet reactivity after percutaneous coronary

intervention：Systematic review and meta-analysis[J].

Am Heart J，2010，160（3）：543-551.